Welcome to our dedicated page for Aptorum Group news (Ticker: APM), a resource for investors and traders seeking the latest updates and insights on Aptorum Group stock.
Aptorum Group Limited (NASDAQ: APM) is described in its public communications as a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology, including orphan oncology indications, and infectious diseases. The company’s news flow also reflects its involvement in healthcare services and diagnostics collaborations, such as the co-development of the PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology.
Recent Aptorum news has highlighted a series of significant corporate and strategic developments. A central theme is the proposed all-stock merger with DiamiR Biosciences Corp., a molecular diagnostics company focused on minimally invasive tests for brain health and other diseases. Multiple joint press releases describe the Agreement and Plan of Merger, the expected ownership split between Aptorum shareholders and DiamiR stockholders, and the intention for DiamiR to become a wholly owned subsidiary of Aptorum, subject to shareholder approvals and customary closing conditions.
News items also cover DiamiR’s activities that are relevant to the combined story, including acceptance of scientific abstracts at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and regulatory milestones such as New York State approval for DiamiR’s APOE genotyping test. These updates emphasize DiamiR’s CLIA-certified, CAP-accredited laboratory, its microRNA-based platform for brain-enriched and inflammation-associated biomarkers, and its focus on brain health and neurodegenerative diseases.
In addition, Aptorum’s news releases describe financing transactions, including registered direct offerings of Class A ordinary shares and concurrent private placements of warrants, with stated uses of proceeds that include funding expenses related to the proposed merger and general working capital. Other announcements address Nasdaq listing matters, such as receipt of a minimum bid price deficiency notice and subsequent regaining of compliance with Nasdaq’s minimum bid price requirement.
Investors and observers following APM news can therefore expect updates on the progress of the proposed merger with DiamiR, scientific and regulatory developments connected to DiamiR’s diagnostics portfolio, Aptorum’s financing activities, and disclosures related to its Nasdaq listing status and SEC filings. The news stream collectively provides insight into how Aptorum presents its evolving strategy across oncology, infectious diseases, and, through the planned merger, brain health-focused diagnostics.
Aptorum Group Limited (NASDAQ: APM) provided a business update and financial results for the six months ending June 30, 2022. The company reported a net loss of $2.7 million, a substantial decrease from $17.1 million in the same period in 2021. Key highlights include successful Phase I trial completions for ALS-4 and SACT-1, alongside progress in the RPIDD program. The commercialization of the NativusWell® nutraceutical targeting women's health has commenced in Hong Kong. The company expects its current cash reserves will support operations for the next 12 months.
Aptorum Group Limited (NASDAQ: APM) will feature in an interview on The RedChip Money Report airing on Bloomberg TV this September 24 at 7 p.m. ET. The discussion, led by CEO Darren Lui, will cover Aptorum's novel therapeutics and diagnostics, along with insights into their U.S. patents. The interview aims to inform investors about the company's advancements in treating unmet medical needs in oncology and infectious diseases. The RedChip Money Report targets small-cap investing and reaches an estimated 73 million homes in the U.S.
Aptorum Group Limited (NASDAQ: APM) has launched NativusWell®, a dietary supplement aimed at supporting women’s health during menopause. The global menopause market, valued at USD 15.4 billion in 2021, is projected to grow at a CAGR of 5.29% from 2022 to 2030. NativusWell® features a non-hormonal ingredient, DOI, recognized for its anti-aging and antioxidant properties. It is currently available on HKTV Mall and online, with plans for global distribution in the US, EU, UK, and China. The company aims to leverage its ecommerce growth to reach a wider audience.
Aptorum Group Limited (NASDAQ: APM) announced significant advancements in its RPIDD technology, which offers rapid pathogen identification. The retrospective and prospective clinical validations involved over 100 patient samples, achieving a 100% agreement with positive clinical data on pathogen identification. The ongoing study aims to expand clinical validation efforts across various countries, including establishing a clinical laboratory in California. The RPIDD technology is designed to enhance pathogen detection in patient blood samples, showcasing substantial analytical sensitivity and specificity.
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology, autoimmune diseases, and infectious diseases. CEO Darren Lui will present at the H.C. Wainwright Global Investment Conference in New York from September 13-16, 2022. The company will also hold one-on-one meetings with institutional investors, emphasizing its ongoing clinical trials and drug development initiatives. For registration, visit H.C. Wainwright.
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) will be featured in an exclusive interview on The RedChip Money Report airing on Bloomberg TV on August 20, 2022, at 7 p.m. ET. The interview, conducted by CEO Darren Lui, will cover the company’s novel therapeutics, diagnostic products, and U.S. patent grants. Targeting unmet medical needs in oncology, autoimmune, and infectious diseases, Aptorum is advancing its therapeutic assets and diagnostic technologies, enhancing its presence in the biopharmaceutical sector.
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical firm, announced that President Darren Lui will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company focuses on developing therapies for unmet medical needs in oncology and infectious diseases. Additionally, Aptorum will conduct online one-on-one meetings with institutional investors during the event. For more details, visit www.aptorumgroup.com.
Aptorum Group Limited (Nasdaq: APM) announced encouraging results from its finalized Phase 1 clinical trial of SACT-1, targeting Neuroblastoma. The trial, conducted with healthy volunteers, demonstrated good safety and tolerability at a 150mg dosage, with no serious adverse events reported. Key bioavailability metrics showed significant improvements under fed conditions, with AUC ratios over 189%. Aptorum plans to meet with the US FDA for a Phase 1b/2a trial application, aiming to initiate testing in pediatric neuroblastoma patients.
Aptorum Group Limited (Nasdaq: APM) reported significant changes in fiscal year results, with a net loss of $27.1 million in 2021 compared to a net income of $4.9 million in 2020, mainly due to a loss on securities investments. The company is progressing in clinical trials for its lead projects, including ALS-4 and SACT-1, with plans to submit an IND application and initiate a Phase 1b/2a study. Additionally, Aptorum aims to commercialize its NativusWell® health supplement in Asia and Europe, pending registration completion.
Aptorum Group Limited (Nasdaq: APM) has received a patent from the US Patent and Trademark Office for its Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics (RPIDD) technology, which offers a unique approach to DNA library preparation. This method significantly enhances the speed and simplicity of diagnostics for infectious diseases. Aptorum has an exclusive licensing agreement with Singapore's A*STAR institution for this technology. The company aims to expedite the clinical validation and pre-commercialization of RPIDD, which could transform clinical diagnostics and improve patient outcomes.